RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 Concomitant TMZ Does Not Improve Effectiveness of WBRT for Brain Metastases from Breast Cancer
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 31
SP 11
OP 11
DO 10.1177/155989771431007
UL http://mdc.sagepub.com/content/14/31/11.1.abstract
AB Temozolomide, an oral alkylating agent, has radiosensitizing properties and has demonstrated promise in previous phase 2 studies involving whole-brain radiation therapy. However, these studies did not include sufficient samples of patients with brain metastases from breast cancer, despite the need for improved treatments for such patients. This article discusses data from a phase 2 prospective randomized multicenter study looking at if the addition of TMZ improves the efficacy of WBRT.